文献速递临床试验与 GCP流行病学与生物统计

高剂量叶酸补充预防子痫前期(FACT研究):双盲III期随机对照国际多中心试验

Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial.
PubMed 文献 · BMJ · 2018-09-12

FACT试验在5国70个产科中心纳入2464名至少有一个子痫前期高危因素的孕妇,随机分为每日4.0 mg叶酸组与安慰剂组,从孕8周至16周末用药至分娩。意向性分析2301人,子痫前期发生率叶酸组14.8%(169/1144)、安慰剂组13.5%(156/1157),相对风险1.10(95%CI 0.90–1.34;P=0.37),组间其他母婴不良结局无差异。

要点

  • 对子痫前期高危孕妇,每日4.0 mg叶酸补充未降低子痫前期风险。
  • 叶酸组与安慰剂组子痫前期发生率分别为14.8%与13.5%,差异无统计学意义。
  • 其他母婴不良结局未见组间差异,不支持以高剂量叶酸预防子痫前期。

核心结论

  • 在至少有一个子痫前期高危因素的孕妇中,妊娠早期后补充4.0 mg/日叶酸不能预防子痫前期。

研究设计与样本

  • 随机、III期、双盲、国际多中心临床试验,2011至2015年在5国70个产科中心随机2464名孕妇(叶酸组1144人、安慰剂组1157人),意向性分析纳入2301人。

主要发现

  • 子痫前期在叶酸组发生169/1144(14.8%),安慰剂组156/1157(13.5%),相对风险1.10(95%CI 0.90–1.34;P=0.37)。
  • 两组其他母婴不良结局均无差异证据。

关键数值与推荐

  • 子痫前期定义为妊娠20周后出现高血压并伴大量蛋白尿或HELLP综合征。
  • 纳入标准为至少一项高危因素:既往高血压、孕前糖尿病(1型或2型)、双胎妊娠、既往子痫前期或体重指数≥35。

临床怎么用

  • 不推荐以每日4.0 mg叶酸补充用于子痫前期高危孕妇的预防。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the efficacy of high dose folic acid supplementation for prevention of pre-eclampsia in women with at least one risk factor: pre-existing hypertension, prepregnancy diabetes (type 1 or 2), twin pregnancy, pre-eclampsia in a previous pregnancy, or body mass index ≥35. DESIGN: Randomised, phase III, double blinded international, multicentre clinical trial. SETTING: 70 obstetrical centres in five countries (Argentina, Australia, Canada, Jamaica, and UK). PARTICIPANTS: 2464 pregnant women with at least one high risk factor for pre-eclampsia were randomised between 2011 and 2015 (1144 to the folic acid group and 1157 to the placebo group); 2301 were included in the intention to treat analyses. INTERVENTION: Eligible women were randomised to receive either daily high dose folic acid (four 1.0 mg oral tablets) or placebo from eight weeks of gestation to the end of week 16 of gestation until delivery. Clinicians, participants, adjudicators, and study staff were masked to study treatment allocation. MAIN OUTCOME MEASURE: The primary outcome was pre-eclampsia, defined as hypertension presenting after 20 weeks' gestation with major proteinuria or HELLP syndrome (haemolysis, elevated liver enzymes, low platelets). RESULTS: Pre-eclampsia occurred in 169/1144 (14.8%) women in the folic acid group and 156/1157 (13.5%) in the placebo group (relative risk 1.10, 95% confidence interval 0.90 to 1.34; P=0.37). There was no evidence of differences between the groups for any other adverse maternal or neonatal outcomes. CONCLUSION: Supplementation with 4.0 mg/day folic acid beyond the first trimester does not prevent pre-eclampsia in women at high risk for this condition. TRIAL REGISTRATION: Current Controlled Trials ISRCTN23781770 and ClinicalTrials.gov NCT01355159.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Wen SW, White RR, Rybak N, et al. Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. BMJ. 2018. PMID: 30209050. doi:10.1136/bmj.k3478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。